OncoMatch/Clinical Trials/NCT07424547
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Is NCT07424547 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies SYS6043 for cancer.
Treatment: SYS6043 — The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may cause, and what dose can be given safely. Researchers will also study how the drug moves through the body and whether the immune system reacts to it. In addition, the study will look for early signs that SYS6043 may help slow or shrink tumors and explore whether the amount of a tumor protein called B7-H3 is related to how well the treatment works. Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive SYS6043 by intravenous infusion once every 3 weeks (Q3W), with 21 days as one treatment cycle until the study doctor determines that study treatment should be stopped based on how well a participant is doing on treatment. * Have safety follow-up (SFU), and long-term follow-up. * Be followed until progression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Small Cell Lung Cancer
Ovarian Cancer
Breast Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic standard of care
disease recurrence or progression during or after systemic standard of care, and should be intolerant of or have no available standard of care therapy
Cannot have received: B7-H3 targeted therapy
Prior B7-H3 targeted therapy
Cannot have received: topoisomerase inhibitor antibody-drug conjugate (trastuzumab deruxtecan)
Previously received drug therapy with topoisomerase inhibitor antibody-drug conjugate (e.g., trastuzumab deruxtecan)
Lab requirements
Cardiac function
lvef ≥ 50% as shown by echo or muga within 28 days prior to enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- BRCR Global · Plantation, Florida
- Florida Clinical Trials Group · Plantation, Florida
- NEXT Oncology Austin · Austin, Texas
- NEXT Oncology San Antonio · San Antonio, Texas
- NEXT Oncology Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify